ARCT

#3502
Arcturus Therapeutics Holdings Inc. Common Stock
8.75 USD
+3.43%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
8.63
8.75
年范围
5.86
24.14
日变化
+3.43%
每月变动
+28.87%
6个月变化
-58.90%
年变化
-15.05%
前一天收盘价
8.46
开盘价
8.64
买价
卖价
最低价
8.63
High
8.75
交易量
22
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 248.7 M
  • Employee 111
  • Founded 2013
  • CEO Joseph E. Payne
  • Website www.arcturusrx.com
  • Headquarter Delaware, United States
  • FIGI BBG00NNW8JK1
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-2.55
市销率
2.05

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA. The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025.

新闻